Business
Opus Genetics Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026
RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026 in the Biotech category. This year’s list shines a spotlight on businesses that are shaping
About this update from Opus Genetics, Inc.
[{"type":"image","alt":"Opus Genetics, Inc.","displaySize":"","headline":null,"caption":"Opus Genetics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":129,"url":"https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1cXWyemNkrNdnQ8pvyVh0g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MQ--/https://media.zenfs.com/en/globenewswire.com/df50c41a115dee0675cbe3b477dc2db0","width":300,"height":129}},"lazy":false},{"type":"text","content":"RESEARCH TRIANGLE PARK, N.C., March 24, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026 in the Biotech category. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations. Alongside the World’s 50 Most Innovative Companies, Fast Company recognizes 720 honorees across 59 sectors and regions.","length":677,"tagName":"p"},{"type":"text","content":"“We are honored to be recognized by Fast Company as one of the world’s most innovative companies,” said George Magrath, M.D., Chief Executive Officer of Opus Genetics. “At Opus Genetics, innovation starts with patients. By combining cutting-edge gene therapy with deep patient engagement, we are redefining how therapies are developed for inherited retinal diseases and working to deliver meaningful outcomes for patients facing blindness.”","length":440,"tagName":"p"},{"type":"text","content":"Over the past 18 months, Opus Genetics has advanced a differentiated pipeline of gene therapies targeting inherited retinal diseases, including OPGx-BEST1 for BEST1-related retinal degeneration and OPGx-LCA5 for LCA5-related mutations, an ultra-rare condition with significant unmet need and a limited patient population globally. The Company has taken a novel, patient-centered approach to development, partnering directly with patients to better define meaningful outcomes that may not be captured by traditional clinical endpoints.","length":534,"tagName":"p"},{"type":"text","content":"The World’s Most Innovative C...